to page content
to site navigation
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
With medical device companies becoming increasingly frustrated with the U.S. Food and Drug Administration, many American companies are looking to Europe to get approval there first. Here are some tips to consider before pursuing the CE Mark.
This week, eMed will be providing coverage of Partnering for Cures, a conference bringing together leaders in biotech research to discuss the healthcare business landscape.
Despite having a great product, your company can suffer from mistakes made during the product launch. Here are five tips on avoiding the mistakes others have made.
At this week's Biotech 2011 conference, speakers from Teva Pharmaceutical Industries and Merck spoke about how biotech companies can survive in this tough regulatory and economic environment.
Commercializing a medical device that's clinically superior is not enough in today's economic climate. Medical device companies need to market products that have both clinical and economic value, says the CEO of Medtronic.
Going global is on the wish list of many U.S. entrepreneurs, especially given the sour American economy. But how to go about it? One leading venture capitalist offers some clues.
Being in the healthcare business is getting tougher when it comes to bringing innovative products to market. A recent conference included discussions about some of the challenges that medical innovators are facing today.
PPD's new CEO Ray Hill brings global knowledge and experience that will help the CRO succeed in today's healthcare business landscape. Read more on CROs and global entrepreneurship.
Pharmaceutical companies are trying to adapt their marketing to an increasingly digital world. To get a handle on this environment, one company has appointed a digital advisory board of marketers from other industries.
Pharma reps at GSK are selling their products in a new way. The emphasis is more on communicating a drug's benefits and risks than trying to sell as much as possible. Read more about this change in approach to sales.
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.